ArticleExperimental physiology2025
Consistency of endothelial function across two consecutive oral contraceptive pill cycles.
Article in Experimental physiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Endocrine enigmas: vascular health in females throughout the lifespan.American journal of physiology. Heart and circulatory physiology · 2025Review
- Consistency of endothelial function across two consecutive oral contraceptive pill cycles.Experimental physiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Oral contraceptive pills (OCPs), composed of an active pill (AP; synthetic hormone) and a placebo pill (PP; synthetic hormone-free) phase, might impact endothelial function across the OCP cycle depending on the synthetic hormone composition (type and dose). Only one study has investigated very low-dose second-generation OCP users, finding impaired endothelial function in the AP versus PP phase. No studies have reported individual changes in endothelial function across OCP phases, and no studies have examined repeatability of endothelial function across multiple OCP cycles. Owing to the consistency of synthetic hormone exposure in OCP users, we hypothesized that group and individual flow-mediated dilatation (FMD) responses to the OCP phase would be consistent across two OCP cycles. Endothelial function was assessed by FMD via Duplex ultrasound in 17 very low-dose second-generation OCP users (19 ± 2 years of age) during the AP phase and PP phase for two consecutive OCP cycles. Individual responses were classified using a threshold of ±2 × typical error. There was a main effect of phase such that FMD was lower in the AP versus PP phase (P = 0.022; AP = 4.3% ± 1.3%, PP = 5.4% ± 1.4%). Threshold analysis revealed no consistent responders, and there was no relationship between Δ%FMD in cycle 1 and cycle 2 (P = 0.220; r = -0.314). Overall, these results suggest that exposure to the synthetic hormones in second-generation OCPs might be detrimental to vascular function, although this was not demonstrated to be a consistent trait-like response at the individual level over two cycles.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.